Health Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Alzheimer Disease
Gamma Secretase Modulators Show Promise in Alzheimer's Disease Animal Model Efficacy Studies, According to Research Conducted by TorreyPines Therapeutics
April 18th, 2008
Gamma secretase modulators (GSMs) have shown promise in Alzheimer's disease animal model efficacy studies, according to research conducted by TorreyPines Therapeutics, Inc. (NASDAQ:TPTX). Presented by Steven Wagner, Ph.D., the company's Chief Scientific Officer, at the recent Keystone Symposium on Alzheimer's Disease, data demonstrated that GSMs provide a more selective mechanism than gamma secretase inhibitors (GSIs). The in vivo research involved internally discovered and optimized compounds that modulate the g-secretase complex without inhibiting its catalytic activity. These GSMs appear to reduce the formation of the longer pathogenic Ab peptides (e.g, Ab42) and...
Source: Health Business Week (2008-04-18)
|
